Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia.

Delvallée M, Mazingue F, Abouchahla W, Delebarre M, Wallet F, Courcol R, Kipnis E, Dessein R.

Pediatr Infect Dis J. 2013 Sep;32(9):962-4. doi: 10.1097/INF.0b013e318298dfb8.

PMID:
23629023
2.

Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.

Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.

J Antimicrob Chemother. 2014 Jan;69(1):176-9. doi: 10.1093/jac/dkt300. Epub 2013 Jul 18.

PMID:
23869050
3.

Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.

Cies JJ, Jain J, Kuti JL.

Pediatr Blood Cancer. 2015 Mar;62(3):477-82. doi: 10.1002/pbc.25287. Epub 2014 Oct 18.

PMID:
25328131
4.

Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.

Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.

Int J Antimicrob Agents. 2005 Jan;25(1):62-7.

PMID:
15620828
5.

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

Kim A, Sutherland CA, Kuti JL, Nicolau DP.

Pharmacotherapy. 2007 Nov;27(11):1490-7.

PMID:
17963458
6.

Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.

Kuti JL, Nightingale CH, Quintiliani R, Nicolau D.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):51-7.

PMID:
12376031
7.

Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.

J Antimicrob Chemother. 2014 Jan;69(1):180-9. doi: 10.1093/jac/dkt304. Epub 2013 Aug 1.

PMID:
23908259
8.

Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial.

Sime FB, Roberts MS, Tiong IS, Gardner JH, Lehman S, Peake SL, Hahn U, Warner MS, Roberts JA.

J Antimicrob Chemother. 2015 Aug;70(8):2369-75. doi: 10.1093/jac/dkv123. Epub 2015 May 7.

PMID:
25953805
9.

Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.

Chen Y, Lu J, Dong M, Wu D, Zhu Y, Li Q, Chen C, Li Z.

Eur J Clin Pharmacol. 2016 Dec;72(12):1479-1488. Epub 2016 Sep 19.

PMID:
27644691
10.

Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.

Mah GT, Mabasa VH, Chow I, Ensom MH.

Ann Pharmacother. 2012 Feb;46(2):265-75. doi: 10.1345/aph.1Q378. Epub 2012 Jan 24. Review.

PMID:
22274145
11.

Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.

Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.

Ann Pharmacother. 2009 Nov;43(11):1747-54. doi: 10.1345/aph.1M304. Epub 2009 Oct 6.

PMID:
19809009
12.

Pharmacokinetic evaluation of piperacillin-tazobactam.

Hayashi Y, Roberts JA, Paterson DL, Lipman J.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1017-31. doi: 10.1517/17425255.2010.506187. Review.

PMID:
20636224
14.
15.

Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?

Attivi D, Gibaud S.

Ann Pharm Fr. 2014 May;72(3):146-51. doi: 10.1016/j.pharma.2013.12.006. Epub 2014 Jan 20. Review.

PMID:
24780830
16.

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.

Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, Baudard M, Legrand O, Rio B, Delmer A, Zittoun R.

Support Care Cancer. 1999 Mar;7(2):89-94.

PMID:
10089089
17.

Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.

Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B.

Crit Care Med. 2008 May;36(5):1500-6. doi: 10.1097/CCM.0b013e318170ba21.

PMID:
18434883
18.

Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Lodise TP Jr, Lomaestro B, Drusano GL.

Clin Infect Dis. 2007 Feb 1;44(3):357-63. Epub 2007 Jan 2.

PMID:
17205441
19.

Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.

Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB.

J Clin Pharmacol. 2015 Aug;55(8):899-908. doi: 10.1002/jcph.505. Epub 2015 May 13.

PMID:
25823963
20.

Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.

Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.

Int J Antimicrob Agents. 2009 Nov;34(5):429-33. doi: 10.1016/j.ijantimicag.2009.07.004. Epub 2009 Sep 1.

PMID:
19726163

Supplemental Content

Support Center